This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure (CARNEBI)

This study has been completed.
Information provided by:
Centro Cardiologico Monzino Identifier:
First received: August 16, 2007
Last updated: September 15, 2010
Last verified: September 2010

The investigators test the hypothesis that different beta-blockers had a different influence on chemoreceptor response and lung diffusion capacity.

Both could influence exercise capacity in normoxic as well as hypoxic conditions.

Condition Intervention Phase
Chronic Heart Failure Drug: carvedilol Drug: bisoprolol Drug: Nebivolol Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function

Resource links provided by NLM:

Further study details as provided by Centro Cardiologico Monzino:

Primary Outcome Measures:
  • exercise capacity [ Time Frame: two months ]

Secondary Outcome Measures:
  • lung diffusion [ Time Frame: two months ]

Enrollment: 60
Study Start Date: July 2007
Study Completion Date: May 2010
Arms Assigned Interventions
Active Comparator: Carvedilol Drug: carvedilol
Active Comparator: Bisoprolol Drug: bisoprolol
Active Comparator: Nebivolol Drug: Nebivolol


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic heart failure patients in stable clinical condition

Exclusion Criteria:

  • No comorbidity
  • NYHA class IV
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00517725

Centro Cardiologico Monzino, University of Milan
Milan, Italy, 20138
Sponsors and Collaborators
Centro Cardiologico Monzino
Principal Investigator: Piergiuseppe Agostoni, MD, PhD Centro Cardiologico Monzino
Study Chair: Giancarlo Marenzi, MD Centro Cardiologico Monzino
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Piergiuseppe Agostoni, Centro Cardiologico Monzino - Univeristy of Milan Identifier: NCT00517725     History of Changes
Other Study ID Numbers: R76-CCM S78/407
Study First Received: August 16, 2007
Last Updated: September 15, 2010

Keywords provided by Centro Cardiologico Monzino:
lung diffusion
heart failure

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antihypertensive Agents
Vasodilator Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic beta-1 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-1 Receptor Antagonists processed this record on August 22, 2017